Comparative analysis of marketed factor VIII products: reply.
作者信息
Reipert B M, Anzengruber J, Scheiflinger F
机构信息
Shire, Vienna, Austria.
出版信息
J Thromb Haemost. 2019 Jan;17(1):233-235. doi: 10.1111/jth.14349. Epub 2018 Dec 24.
Abstract
摘要
相似文献
1
Comparative analysis of marketed factor VIII products: reply.市售凝血因子VIII产品的比较分析：回复
J Thromb Haemost. 2019 Jan;17(1):233-235. doi: 10.1111/jth.14349. Epub 2018 Dec 24.
2
Comparative analysis of marketed factor VIII products: comment.市售凝血因子VIII产品的比较分析：评论
J Thromb Haemost. 2019 Jan;17(1):232-233. doi: 10.1111/jth.14321. Epub 2018 Dec 24.
3
Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.市售因子 VIII 产品的比较分析：重组产品在可溶性蛋白聚集体和亚可见颗粒方面并不相同。
J Thromb Haemost. 2018 Jun;16(6):1176-1181. doi: 10.1111/jth.14125. Epub 2018 May 11.
4
Identification of aggregates in therapeutic formulations of recombinant full-length factor VIII products by sedimentation velocity analytical ultracentrifugation.采用沉降速度分析超速离心法鉴定重组全长因子 VIII 产品治疗制剂中的聚集体。
J Thromb Haemost. 2018 Feb;16(2):303-315. doi: 10.1111/jth.13917. Epub 2018 Jan 11.
5
Clogging up the pipeline: factor VIII aggregates.堵塞管道：凝血因子 VIII 聚集体
Blood. 2020 May 21;135(21):1825-1827. doi: 10.1182/blood.2020005450.
6
Increasing levels of von Willebrand factor and factor VIII with age in patients affected by von Willebrand disease: REPLY from original authors Biguzzi et al.血管性血友病患者中血管性血友病因子和凝血因子 VIII 水平随年龄增长而升高：原作者比古齐等人的回复
J Thromb Haemost. 2021 Jan;19(1):310. doi: 10.1111/jth.15150.
7
Reply to: "Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis".回复：“因子VIII作为非肝硬化门静脉血栓形成患者复发性血栓形成的潜在预测指标”
J Hepatol. 2023 Mar;78(3):e111-e112. doi: 10.1016/j.jhep.2022.11.026. Epub 2022 Dec 9.
8
Characterization of protein unable to bind von Willebrand factor in recombinant factor VIII products.重组凝血因子VIII产品中无法结合血管性血友病因子的蛋白质的特性分析。
J Thromb Haemost. 2021 Apr;19(4):954-966. doi: 10.1111/jth.15257. Epub 2021 Feb 24.
9
[Plasma transfusion in hemophilia. VIII. Effect of various plasma products on hemophilia A].[血友病中的血浆输注。VIII. 各种血浆制品对甲型血友病的影响]
Ned Tijdschr Geneeskd. 1963 Jan 26;107:155-9.
10
Reply to the letter by Iorio.对伊奥里奥来信的回复。
Haemophilia. 2017 May;23(3):e248-e249. doi: 10.1111/hae.13248. Epub 2017 Apr 21.
本文引用的文献
1
Comparative analysis of marketed factor VIII products: comment.市售凝血因子VIII产品的比较分析：评论
J Thromb Haemost. 2019 Jan;17(1):232-233. doi: 10.1111/jth.14321. Epub 2018 Dec 24.
2
Effects of Product Handling Parameters on Particle Levels in a Commercial Factor VIII Product: Impacts and Mitigation.产品处理参数对商业因子 VIII 产品中颗粒水平的影响：影响和缓解。
J Pharm Sci. 2019 Jan;108(1):775-786. doi: 10.1016/j.xphs.2018.08.022. Epub 2018 Sep 6.
3
Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.市售因子 VIII 产品的比较分析：重组产品在可溶性蛋白聚集体和亚可见颗粒方面并不相同。
J Thromb Haemost. 2018 Jun;16(6):1176-1181. doi: 10.1111/jth.14125. Epub 2018 May 11.
4
Immunogenicity of Therapeutic Protein Aggregates.治疗性蛋白质聚集体的免疫原性。
J Pharm Sci. 2016 Feb;105(2):417-430. doi: 10.1016/j.xphs.2015.11.002.
5
Factor VIII products and inhibitor development in severe hemophilia A.VIII 因子产品与严重甲型血友病抑制物的产生。
N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024.
6
Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.高度聚集的抗体疗法可以增强体外固有和晚期 T 细胞免疫反应。
J Biol Chem. 2012 Jul 20;287(30):25266-79. doi: 10.1074/jbc.M111.330902. Epub 2012 May 14.
7
A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding.蛋白质聚集动力学的Lumry-Eyring成核聚合模型：1. 预平衡去折叠的聚集过程
J Phys Chem B. 2007 Jul 12;111(27):7897-913. doi: 10.1021/jp070212j. Epub 2007 Jun 16.
8
Genetic risk factors for inhibitors to factors VIII and IX.凝血因子VIII和IX抑制物的遗传风险因素。
Haemophilia. 2006 Dec;12 Suppl 6:15-22. doi: 10.1111/j.1365-2516.2006.01361.x.
9
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.VIII因子和IX因子抑制剂的基本方面以及非遗传风险因素的影响。
Haemophilia. 2006 Dec;12 Suppl 6:8-13; discussion 13-4. doi: 10.1111/j.1365-2516.2006.01360.x.
10
Theoretical approaches to protein aggregation.蛋白质聚集的理论方法。
Protein Pept Lett. 2006;13(3):287-93. doi: 10.2174/092986606775338407.
Zotero 插件